We hypothesize that patients with high-grade MTC, who exhibit a tendency towards high expression of DLL3 and an expression profile similar to SCLC-A, may benefit from inclusion in clinical trials using compounds that target DLL3. This evidence concerns the gene DLL3 and small cell lung carcinoma.